GE Healthcare Technologies Inc. is participating in the €25.3 million (US$27.8 million) Thera4care project that aims to expand the use of theranostics in Europe. The 29 partners involved in the project will develop new cancer treatment tools, strengthen the manufacture and supply of radiotheranostic, and optimize the clinical use of radiotheranostics.

Certis Oncology Solutions Inc. filed for protection of its artificial intelligence platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers.

Exact Sciences Corp.’s Cologuard Plus received U.S. FDA pre-market approval as a non-invasive colorectal cancer home screening test. The next-generation, stool-based assay, developed in conjunction with the Mayo Clinic, reduces false positives by 30% compared to the original Cologuard test without diminishing its sensitivity for cancer or advanced adenomas.

Varian Medical Systems Inc. launched its Hypersight imaging solution for its Truebeam and Edge linear accelerators across the Asia Pacific region, providing clinicians with better image quality, enhancing their ability to deliver more precise radiation treatments.

Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. The companies hope that the gBRCA pre-screening solution will not only transform patients’ lives but bring value to health care systems.

A study presented at the American Society for Radiation Oncology on Oct. 1 offers promise for the treatment of high-grade gliomas using Elekta AB’s Unity MR-Linac system.

Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get skin checks that could end up costing them their lives.

Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get skin checks that could end up costing them their lives.

The Nov. 20-21 meeting of the digital health advisory committee will discuss the use of generative artificial intelligence algorithms in medical devices with a focus on the total product life cycle – a theme that suggests a concern on the agency’s part regarding the reliability of these algorithms’ output.

Qure.ai Technologies Private Ltd.’s Qxr artificial intelligence-powered chest X-ray interpretation system identified high-risk pulmonary nodules an average of 32 months before physicians diagnosed lung cancer, a study presented September 8 at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer in San Diego found.